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Abstract
Background: Patients with primary immunodeficiency disease (PID) who survive to adulthood and willing to have
a child mostly are worried whether their disease affects their fertility and/or pregnancy and also if their child would
be predisposed to PID.
Case presentation: We report the outcome of conception, pregnancy and their management in 9 families with
definite diagnosis of PID. A chronic granulomatous disease subject with an uneventful pregnancy developed fungal
sacral osteomyelitis few weeks after delivery. A pregnant common variable immunodeficiency disease (CVID) patient
with idiopathic thrombocytopenia had platelet count dropped before delivery. A sever neutropenic mother who
refused to get IFNγ delivered two healthy children. A CVID case intolerant to IVIg with eclampsia and PTE delivered a
baby. Another CVID female gave birth to a baby without being on any treatment since she was not diagnosed with
immunodeficiency disease at that time. A healthy girl was implanted via preimplantation gender selection in a family
who owned a Wiskott Aldrich-affected son. A family who had two children with Ataxia Telangiectasia used donated
oocyte for their 3rd child. Prenatal genetic diagnosis was used to screen the fetus for the impaired BTK and CVID genes
detected in sibling and father respectively in 2 separate families.
Conclusion: Pregnancy in PID patients is more complex than normal population. Because, not only it has the chance
of being inherited by the offspring, but also there are some risks for the mother if she has any kind of immunity
component defects. So consultation with a clinical geneticist is crucial to choose the best available approach. They also
should be observed and followed by a clinical immunologist to take the best possible safe care.
Keywords: Ataxia telangiectasia, CGD, CVID, Conception, Fertility, PGD, Pregnancy, Primary immunodeficiency disease,
Wiskott-Aldrich
Background
Primary immunodeficiency diseases (PID) are a group of
inherited disorders in which components of the immune
system are missing or do not function properly [1]. Pa-
tients usually experience their first symptoms during
childhood, although some types may not be recognized
until later in life. Individualized treatment of the burden
of PID has reduced the mortality and morbidity, so pa-
tients often survive into adulthood. The wish to conceive
in PID affected parents may be negatively influenced by
the fear of complications and concerns about inheritance
patterns. Some cases with common variable immuno-
deficiency disease (CVID) have been studied during
pregnancy period but it has been much more focused on
the treatment rather than prevention of giving birth to a
PID child and/or complications due to pregnancy. Preg-
nancy in other PID types except CVID is not studied
much. This study presents some families with definite
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diagnosis of PID who conceived naturally or by in-vitro
fertilization (IVF) with the consultation of a clinical gen-
eticist, they were tightly observed and managed by the
obstetrician and the clinical immunologist during their
pregnancy and also were followed for any likely compli-
cation due to pregnancy.
Case presentation
Case 1
A 23 year-old patient with Chronic Granulomatous Disease
(CGD) gave birth to a normal healthy male. During preg-
nancy IFNγ was discontinued and through control visits
acute phase reactants were evaluated with no increase.
Diagnosis of CGD was established at 8 years old due to re-
current pneumonia, empyema, oral ulcers, skin abscess and
cervical mycobacterial lymphadenitis. Genetic analysis re-
vealed p47-phox gene mutation. She was born out of con-
sanguineous marriage and her sister had been diagnosed
with CGD as well. Four weeks after delivery she went to
emergency department complaining of low back pain irradi-
ated to left gluteal, sacral and lumbosacral area. Laboratory
workup showed leukocytosis (WBC= 11,700 cell/mcL) and
increased levels of liver enzymes (SGPT= 131 U/L, nor-
mal:7–55, SGOT=56 U/L normal:8–45, ALP = 1588 U/L,
normal:45–115). Abdominopelvic US revealed granuloma-
tous lesions in uterus and liver. Contrast lumbosacral MRI
showed enhancement in L5 and S1 suggesting infection or
inflammation. Pathology Department reported granuloma-
tous lesion and PCR positive for Aspergillus fumigatus. She
was diagnosed with fungal osteomyelitis and went under
treatment with IFNγ and Voriconazole for 12 weeks with
good response. In follow-up tests liver enzymes decreased
(SGPT= 54 U/L, SGOT=24 U/L, ALP= 423 U/L) and
granulomatous lesions disappeared.
Case 2
A 23 year-old patient with CVID whose diagnosis was done
7 years before pregnancy when she was 16 years old with
clinical history of lower and upper recurrent respiratory tract
infections and autoimmune thrombocytopenia. Genome
analysis showed heterozygous missense variant in exon 3 of
CDX1 gene. Blood tests at 5 weeks of gestation showed IgM
of 0.8 g/L (0.3–2.5), a total IgG of 5.6 g/L (normal 6.0–16.0),
and IgA of 0.7 g/L (normal 0.8–5). During pregnancy she re-
ceived 500 mg/kg of IVIg every 3 weeks. In the 2nd trimester
of pregnancy she presented idiopathic thrombocytopenia,
which was managed with higher doses of IVIg (800 mg/kg)
with no clinical manifestation. Platelet count dropped to
16x103platelets/mm3 abruptly before her cesarean section
and need hindered urgent platelet infusion before delivery.
Ultimately she gave birth to a full term, normal healthy child
and few days after delivery platelet count reached normal
level (Fig. 1).
Case 3
A patient with JAGN1 gene mutation suffering from Severe
Congenital Neutropenia (SCN). Initially she was evaluated
for recurrent pneumonia, visceral abscesses, oral ulcers and
severe dental problems at 23 years old. Her first pregnancy
was at 25-year-old with no complication. She gave birth to a
healthy male whose genomic analysis showed he is not a
carrier. She became pregnant again at the age of 37 and just
delivered a healthy baby. The patient refused to receive
G-CSF all these years and has attended the clinic with pneu-
monia, hemoptysis and a drop in her ANC twice in her 2nd
pregnancy at 2nd and 3rd trimester accompanied with se-
vere neutropenia (Fig. 2). Each time she received antibiotics
for pneumonia and became well again. At 38w of gestation
she fell down from stairs and her fibula has fractured.
Prophylactic antibiotics were administered in order to avoid
progression to osteomyelitis. Her neutrophil count was in
normal range during hospitalization and delivery (ANC>
1500). She breast-fed her baby from birth and the baby is
infection-free and thriving, with normal neutrophil count.
Case 4
A 29 year-old woman, a case of CVID who was
unrecognized till age 22. She had autoimmune hepatitis
(AST=) with false negative markers due to immunodefi-
ciency. Biopsy from duodenum showed celiac-like disease.
Fig. 1 Platelet count in different gestational age
Fig. 2 WBC count and ANC in different gestational age
Sheikhbahaei et al. BMC Pregnancy and Childbirth  (2018) 18:299 Page 2 of 6
She was on immunosuppressant drugs before her definite
diagnosis. Her genetic result revealed NF-κB2 frameshift
mutation. She had history of recurrent cold, hospitalization
for pneumocystis jiroveci, atopy and allergy. Immunoglobu-
lin levels were as follows; IgG = 7.05 g/L (normal: 6–16),
IgM= 0.3 g/L (normal: 0.5–2.5), IgA = 0.5 g/L (normal:
0.8–4), IgE = 2 g/L (normal < 0.002). Flowcytometry result
demonstrated CD4 = 59%, CD8 = 14%, CD16 + 56 = 14%.
While she was started on IVIg therapy she showed allergic
reaction to the product. IVIg was discontinued and the pa-
tient was reluctant to take it anymore. She was returned to
use immunosuppressive drugs including cellcept and
prednisone. She became pregnant and all drugs were dis-
continued. Strangely her liver enzymes became normal
(AST = 20, ALT = 32). Eclampsia developed at 24w of ges-
tation, handled under supervision of her obstetrician. She
received heparin for 1 month as she had tachypnea and
dyspnea and was suspicious to PTE at 30w. Her Immuno-
globulin level at 34w of gestation was IgG = 5.1 g/L and
IgM= 0.42 g/L and IgA = 0.49 g/L. She has born her child
at 38w. The baby is well and we are waiting for her im-
munoglobulin level and other laboratory results to decide
on vaccination.
Case 5
A 26 year-old woman is recently known for CVID. She
was referred to our clinic for extensive bilateral bronchiec-
tasis. Her laboratory results showed hypogammaglobuli-
nemia (IgM= 0.0.14 g/L normal: 0.4–2.6, IgG = 4.1 g/L
normal: 6.5–18, IgA = 0.05 g/L normal: 0.7–3.6). She is
getting IVIg now but she became pregnant 2 years ago
while her diagnosis was not made and no immunotherapy
was given. She had severe dyspnea and suffered from re-
current pneumonia during her pregnancy that was treated
with antibiotic. She gave birth to a healthy boy baby. We
do not have the immunoglobulin level of the child at birth
but according to the mother’s statement he had no serious
infection in his first 6 months of life.
Case 6
Male patient with CVID born out of a consanguineous
marriage. Whole exome sequencing revealed 2 heterozy-
gous mutations in TNFRSF13B gene. This male patients
married a healthy appeared woman and his wife became
pregnant. During pregnancy, his wife underwent chorionic
villus sampling (CVS), fetal DNA was obtained and re-
vealed homozygous mutation in TNFRSF13B gene sug-
gesting a strange fact that the mother is carrier of a
mutation in the same gene while she is not a family mem-
ber of the father. The boy infant was born and advised not
to receive any live attenuated vaccine. He was brought to
our clinic for further evaluation and hypogammaglobuli-
nemia was found in his lab data in his 6-month-old visit
(IgG = 1.5 g/L, IgA = 0.1 g/L, IgM = 0.2 g/L).
Case 7
A male child with meningitis, recurrent upper and lower
respiratory infections was diagnosed with X-linked Agamma-
globulinemia known as Bruton’s tyrosine kinase (Btk) defi-
ciency. The parents conceived their second child before
genetic counseling. Chorionic villus sampling (CVS) was
performed in 12 weeks gestation, DNA is extracted and
sequenced. The mutation exists in the fetus as well. Fetal
DNA sample was checked for maternal DNA contamination
by short tandem repeats markers. Although in this case abor-
tion was legally allowed, the parents chose to preserve the
boy offspring. We only advised them avoid live vaccination
for him.
Case 8
Two siblings were born from a consanguineous union and
diagnosed with Ataxia-Telangiectasia during infancy. The
boy died from gastric cancer in early childhood but the
girl overcame recurrent upper and lower respiratory infec-
tions by monthly IVIg. After genetic counseling parents
decided to have another baby using a donor egg. The re-
cipient couple underwent standard IVF process. Collected
oocytes were inseminated via ICSI (intracytoplasmic
sperm injection). Among them 3 fertilized successfully
4 days later and one embryo was transferred to the pre-
pared uterine of the recipient. CVS was performed at 12w
of gestation and genetic result was normal.
Case 9
Patient diagnosed with Wiskott-Aldrich syndrome due to
thrombocytopenia, anemia, severe eczema, molluscum con-
tagiosum and hypogammaglobulinemia. Genetic analysis
revealed homozygous mutation in exon 8. The parents re-
ceived genetic counseling about inheritance pattern of the
disease and they chose to have another baby via PGD gen-
der selection. In this process, hormonal stimulation followed
by oocyte aspiration is required for IVF. Blastomere from an
8-cell human cleavage-stage embryo was biopsied on day 4
after IVF and single cell PCR was applied to provide infor-
mation about the sex chromosomes of the embryo. An XX
embryo was transferred to uterine cavity and now they own
a 2-month-old healthy daughter.
Discussion
Most PIDs are inherited in one out of the three patterns of
inheritance including autosomal recessive (AR), X-linked
recessive (XR) and autosomal dominant (AD). In the XR
inheritance pattern which asymptomatic parents have an
affected son it has been suggested to select the child gender
prior to conception. According to Islamic law, sex selection
for X-linked disorders is allowed [2, 3], as we have done for
case 8 which was affected by WAS.
Regarding the concerns of the parents who have the dis-
ease or have an affected child, some methods to determine
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the chance of inherit the disease to the child before delivery
are available. Preimplantation genetic diagnosis (PGD) is
one of the useful established procedures for couples who are
at high risk of bearing a child with single gene disorder. Im-
plantation of an unaffected embryo via IVF in individuals
with SCID, LAD, XL-agammaglobulinemia and AT have
been previously reported [4–7]. Evidences supporting the
efficacy of PGD in detection of some immunodeficiencies
such as Wiskott-Aldrich syndrome, X-linked hyper-IgM
syndrome (HIGM), X-linked hypohidrotic ectodermal dys-
plasia with immune deficiency (HED-ID), ataxia telangiecta-
sia and Omenn syndrome and transferring healthy embryos
are also available [8]. Gamete donation suggestible for infer-
tile couples could assist affected volunteer or carrier parents
to ascertain wellness of their baby [9]. Couples at risk could
benefit from prenatal diagnosis via chorionic villus sampling
(CVS) and amniocentesis (12-16w) early in pregnancy. Pre-
natal genetic analysis in fetuses born to PID carriers allows
them to choose the optimal management before childbirth
[10]. Additionally CVS had been applied to ascertain the
gender of the fetus in X-linked immunodeficiencies such as
WAS, X-CGD, IPEX, XLA and SCID [10–12]. Early diagno-
sis of life-threatening congenital disease provides the chance
of stop pregnancy. A couple assessed for CD40L deficiency
(HIGM) opted for voluntary abortion to avoid giving birth
to an affected child [13].
It is important to know that patients with severe com-
bined immunodeficiency, hyper IgM and Wiskott-Aldrich
should be kept away from all live vaccines such as BCG and
OPV. Patients with CVID are also not recommended to be
vaccinated with OPV and VZV. Newborns with suspected
immunodeficiency who did not have definite prenatal diag-
nosis or have an older sibling with one of the PIDs men-
tioned above should avoid use of live vaccines [14].
This patient was affected by sacral bone osteomyelitis.
Among PIDs, CGD holders show the highest susceptibil-
ity for Aspergillus osteomyelitis with the most frequent
sites of infection being vertebrae, cranium, ribs and long
bones [15–17]. It has been suggested that infections with
Aspergillus nidulans in CGD cases could be acquired by
hematogenous dissemination [16]. Osteomyelitis of pubis
symphysis in pregnancy has been previously reported
[18, 19], sporadic cases of osteomyelitis in vertebra and
iliac bone with gram-positive cocci, MRSA and Salmonella,
as well [20–22]. It has been hypothesized that pregnancy
sacroiliitis could be associated with microscopic areas of in-
jury on the joint surfaces produced by the changes during
pregnancy [23]. Antibacterial and antifungal prophylaxis is
the cornerstone of prevention in CGD patients. IFNγ is an
immunotherapy administered in patients with CGD but it
is assigned to pregnancy category C by the FDA. Studies on
primates have shown that it causes abortion at 100 times
the human dose. As there is no controlled data in human
pregnancy, it has been held in our case while she became
pregnant. Also there is no evidence on the excretion of
interferon gamma-1b into human milk and we avoid using
the drug in breastfeeding. This patient developed granu-
loma in visceral organs after cessation of IFNγ and healed
after re-administration of the drug. In recent years, the
routine use of antimicrobial prophylaxis such as
trimethoprim-sulfamethoxazole (TMP-SMX) and newer
azole drugs such as posaconazole and isovuconazole has re-
duced the mortality and morbidity of patients with CGD
but a major concern of a pregnant woman is teratogenicity
of the drugs. Although Amphotericin B has known toxicity
but still is the first-choice parenteral drug for fungal infec-
tion during pregnancy. Topical drugs can be safely applied
due its limited absorption, but most oral azoles are found
to have teratogenic effects throughout the first trimester es-
pecially high-dose fluconazole. Although recent analysis re-
vealed additional safety data on using itraconazole and lipid
derivatives of Amphotericin B, there is still no proven anti-
fungal prophylactic agent known to be completely safe in
pregnancy [24–26]. We can take benefit of Cotrimoxazole
in second trimester and even in early 3rd trimester, but
TMP-SMX is contraindicated in first and third trimester of
pregnancy and it would be better to use penicillin or 3rd
generation of cephalosporin as antibacterial prophylactic
treatment in this period [25].
Regarding to predominantly antibody deficiencies an
approved protocol on the management of CVID or
HIGM in pregnancy does not exist, there are some case
reports of success [27]. It is recommended to use
exogenous intravenous IgG (IVIg) in CVID mothers
during pregnancy and breastfeeding [28–31]. It has
been demonstrated that Regular IVIG therapy (RIT)
should be administered in early stages of pregnancy
since it takes 3–6 months to achieve the protective
level of IVIg in the mother and the infant [26, 32]. In
patients with decreased level of immunoglobulins,
without RIT transfer of IgG to the fetus may decrease.
Lack of sufficient protective antibody predisposes fetus
to intrauterine infections. Also the risk of infection in
early childhood is increased as humoral immune system
of newborn is not mature enough. Due to haemodilu-
tion during pregnancy there is a depletion in the level
of maternal IgG concentration. So, higher dose of IVIG
is required to reach the placenta. It is also suggested to
do a booster dose of IVIG prior to delivery regarding
the patients’ IgG trough levels. Routinely 0.4–0.6 g/kg
is administered in pregnant women [30, 31]. There was
a study reported 2 pregnant CVID women who de-
clined to receive IVIg, although IgG levels of mothers
were low, fetuses maintain normal IgG level. The the-
ory behind the fact was increasing the transport of IgG
from mother to fetus, when maternal IgG is low by up-
regulation of IgG Fc receptors in the endosome of the
syncytiotrophoblast [33].
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Conclusion
For PID patients, pregnancy is more complicated because
not only the child can inherit the disease but also the
mothers are at risk because of defects in the immune sys-
tems. So genetic counseling is mandatory. This will allow
PID affected families to find the best available approach.
Management of the disease during and after pregnancy
should be monitored by a clinical immunologist to ensure
the best safe care.
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